ライフサイエンスコーパス: dimercaptosuccinic acid

1 (7)(DMSA)(4), where DMSA represents meso-2,3-dimercaptosuccinic acid.

2 (99m)Tc-labeled dimercaptosuccinic acid ((99m)Tc-DMSA) accumulates in th

3 Serial technetium-99m-labeled dimercaptosuccinic acid ((99m)Tc-DMSA) renal scintigraph

4 renal parenchymal disease on (99m)Technetium-dimercaptosuccinic acid ((99m)Tc-DMSA) scintigraphy.

5 These oral chelators, meso-2,3-dimercaptosuccinic acid and sodium 2,3-dimercapto-1-prop

6 cated in organic mercury exposures, meso-2,3-dimercaptosuccinic acid and sodium 2,3-dimercapto-1-prop

7 Dimercaptosuccinic acid-coated SPIONs are internalized a

8 exposed animals with the chelating agent 2,3-dimercaptosuccinic acid completely reversed the effect o

9 The As(III) chelator dimercaptosuccinic acid did not block the transfer from

10 We also did a metastable 99mTc-labelled dimercaptosuccinic acid (DMSA) assay and contrast cystog

11 immersion into aqueous solutions of meso-2,3-dimercaptosuccinic acid (DMSA) at increasing concentrati

12 to-1-propanesulfonic acid (DMPS) or meso-2,3-dimercaptosuccinic acid (DMSA) caused a significant redu

13 One trial (n = 780) of dimercaptosuccinic acid (DMSA) chelation therapy found r

14 Pyronin Y (PY) and chelating agent meso-2,3-dimercaptosuccinic acid (DMSA) for the simultaneous dete

15 Renal cortical imaging with 99mTc-dimercaptosuccinic acid (DMSA) has become the imaging te

16 In this work, renal imaging using (99m)Tc-dimercaptosuccinic acid (DMSA) projects are presented as

17 he newborn babies soon after delivery, and a dimercaptosuccinic acid (DMSA) radioisotope scan at 3 mo

18 toacetyltriglycine (MAG3) renograms, (99m)Tc-dimercaptosuccinic acid (DMSA) renal cortical scans, (99

19 Quantitative 99mTc-dimercaptosuccinic acid (DMSA) renal uptake was studied

20 ictive factor for areas of lack of uptake on dimercaptosuccinic acid (DMSA) scans (P < 0.01).

21 eiving kidney transplants had early and late dimercaptosuccinic acid (DMSA) scans to detect acquired

22 year later, ultrasonography, technetium 99m-dimercaptosuccinic acid (DMSA) scintigraphy, contrast ma

23 enal length measurements obtained with 99mTc-dimercaptosuccinic acid (DMSA) SPECT.

24 ciations between blood lead, tibia lead, and dimercaptosuccinic acid (DMSA)-chelatable lead and measu

25 cificity for APN were compared with those of dimercaptosuccinic acid (DMSA).

26 ully addressed by complexation with meso-2,3-dimercaptosuccinic acid (DMSA).

27 he results were compared with the results of dimercaptosuccinic acid (DMSA, as used drug).

28 treatment with the oral chelating agent 2,3-dimercaptosuccinic acid (DMSA, succimer).

29 ; renal scanning with technetium-99m-labeled dimercaptosuccinic acid has also been endorsed by other

30 A new drug, DMSA (meso 2,3-dimercaptosuccinic acid) has been approved for oral chel

31 of photopenia plus contour change on a late dimercaptosuccinic acid renal scan (obtained at study ex

32 rences (SFD) were quantified with technetium-dimercaptosuccinic acid renography.

33 Dimercaptosuccinic acid scans provide important informat

34 Ultrasounds and dimercaptosuccinic acid scintigraphies (DMSA) of all pat

35 ify patients at risk for kidney damage, with dimercaptosuccinic acid scintigraphy as the reference me

36 phantoms have been used to simulate (99m)Tc-dimercaptosuccinic acid SPECT images.

37 thiol-based compounds dimercaptopropanol and dimercaptosuccinic acid suppressed toxicity in both HD c

38 luster, Ag(4)Ni(2)(DMSA)(4) (DMSA = meso-2,3-dimercaptosuccinic acid) was synthesized and characteriz